1. Clinical Overview
Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist. In the 2mg strength, it is primarily used in India for the management of moderate to severe acute pain (often post-operative) and as a component of opioid substitution therapy (OST) for opioid dependence, though the latter typically uses a sublingual formulation. It provides potent analgesia with a ceiling effect on respiratory depression, making it safer than full agonists in overdose.
| Onset | Duration | Bioavailability |
|---|---|---|
| Sublingual: 30-60 minutes; Intravenous: Within 10-15 minutes; Intramuscular: 15-30 minutes. | 6 to 8 hours for analgesia; up to 24-72 hours for opioid blockade in dependence treatment. | Sublingual: 30-55%; Intramuscular/Intravenous: 100%. |
2. Mechanism of Action
Buprenorphine binds with high affinity and slow dissociation to mu-opioid receptors in the central nervous system. As a partial agonist, it produces a sub-maximal analgesic effect compared to full agonists like morphine. It also acts as an antagonist at the kappa-opioid receptor, which may contribute to its unique effects, including a lower incidence of dysphoria.
3. Indications & Uses
- Management of moderate to severe acute pain (e.g., post-operative pain)
- Opioid Substitution Therapy (OST) for opioid dependence (as part of a comprehensive treatment program)
4. Dosage & Administration
Adult Dosage: **Pain:** Sublingual: 0.2-0.4 mg every 6-8 hrs as needed. IM/IV: 0.3 mg every 6-8 hrs. **OST:** Induction and maintenance doses are highly individualized, starting typically at 2-4 mg sublingually, titrated upwards to 8-24 mg/day based on control of withdrawal symptoms. Must be initiated under supervision.
Administration: **Sublingual tablet:** Place under the tongue and allow to dissolve completely (takes 5-10 minutes). Do not chew, swallow, or ingest for at least 5 minutes after dissolution. Avoid eating or drinking until tablet is fully dissolved. **For OST:** Administration is directly observed at the center initially. Take-home doses may be permitted after stabilization as per program rules.
5. Side Effects
Common side effects may include:
- Nausea, vomiting
- Constipation
- Headache
- Dizziness, vertigo
- Sedation, drowsiness
- Sweating
- Dry mouth
- Miosis (pinpoint pupils)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death. Risk is highest with parenteral use and abuse. | Major - Contraindicated for non-medical use. Combined use in therapy requires strict medical supervision. |
| Other CNS Depressants (Alcohol, Barbiturates, Sedative-hypnotics) | Additive CNS depression, increased risk of respiratory depression and hypotension. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir, Grapefruit juice) | Increased buprenorphine plasma levels, potentiating effects and toxicity. | Moderate |
| CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased buprenorphine plasma levels, potentially reducing efficacy and precipitating withdrawal. | Moderate |
| Full Opioid Agonists (e.g., Morphine, Methadone, Fentanyl) | Buprenorphine may block the effects of full agonists and precipitate acute withdrawal in opioid-dependent patients. | Major |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol) | Potential increased risk of serotonin syndrome. | Moderate |
| Anticholinergics | Increased risk of urinary retention and constipation. | Moderate |
| Antihypertensives | Potentiation of hypotensive effects. | Moderate |
7. Patient Counselling
- DO take the medication exactly as prescribed by your doctor.
- DO allow sublingual tablets to dissolve completely under your tongue.
- DO inform all your healthcare providers you are taking buprenorphine.
- DO keep the medicine in a secure place, out of reach of others.
- DONT crush, chew, snort, or inject the tablets.
- DONT consume alcohol or take other sedatives/ tranquilizers.
- DONT drive or operate heavy machinery until you know how the medicine affects you.
- DONT stop taking the medicine suddenly if used for dependence, as it can cause withdrawal.
8. Toxicology & Storage
Overdose: CNS depression (somnolence progressing to coma), respiratory depression (less severe than full agonists due to ceiling effect), miosis, hypotension, bradycardia, skeletal muscle flaccidity, cold/clammy skin.
Storage: Store at room temperature (15-30°C), protected from light and moisture. Keep in the original blister pack or container. Keep out of reach of children and in a locked cabinet to prevent misuse and theft. Do not use after the expiry date. Dispose of unused tablets safely as per pharmacy guidelines or return to the dispensing center.